Akums Group从2027年开始,为在欧洲供应口服液体药品签订了2 000万欧元的交易。 Akums Group secures €200M deal to supply oral liquid medications in Europe, starting 2027.

Akums集团是一家制药厂,它与一家全球制药公司签署了一项2亿欧元的协议,在欧洲生产和供应口服液体药品。 Akums Group, a pharmaceutical manufacturer, has signed a €200 million deal with a global pharmaceutical company to produce and supply oral liquid medications in Europe. 该协议包括为开发和批准程序预付1亿欧元的预付款,商业供应定于2027年开始,持续到2032年。 The agreement includes an upfront €100 million payment for development and approval processes, with commercial supply set to begin in 2027 and run through 2032. Akums的目标是到2026年底获得欧洲对其新的口服液态制造单位的批准,扩大其在该区域的存在。 Akums aims to gain European approval for its new oral liquid manufacturing unit by the end of 2026, expanding its presence in the region.